back to conferences



11 - 13 September, 2020


ACTRIMS-ECTRIMS Joint Virtual Meeting (MSVIRTUAL2020)

Quanterix is proud to sponsor the upcoming ACTRIMS-ECTRIMS Congress 2020, the forum to explore advances in the field of MS with scientists, researchers, clinicians and health care professionals from all over the world.

More Conference Information

Abstracts Of Presentations And Posters Featuring Simoa Technology At Msvirtual2020:

Presentation Type/Number 


  1. FC04.03 – High plasma glial fibrillary acidic protein levels predict disability milestone EDSS 7 in non-active secondary progressive multiple sclerosis

J. Kuhle

  1. LB01.03 Neutrophil granulocyte markers in cerebrospinal fluid differentiate NMOSD and anti-MOG antibody associated disease from MS in acute disease phase

D. Leppert

  1. LB01.06 – Interrupting disease modifying treatment for pregnancy in multiple sclerosis – effect on disease activity and serum neurofilament light chain

Ö. Yaldizli

  1. LB1178 – Monitoring of blood neurofilaments improves stratification of disease activity in multiple sclerosis

T. Uher

  1. LB1219 – Normal serum NFL levels: a proposal of cut-off strategy definition for the clinical practice 

P. Valentino

  1. LB1220 – Real-life experience with sNFL in Multiple Sclerosis patients, as monitoring and treatment decision biomarker 

P. Valentino

  1. LB1221 – Applicability of sNFL in Multiple Sclerosis as additional measure in clinical practice and implications in NEDA-3 evaluation.   

A. Bertolotto

  1. P0032 – Baseline serum Neurofilament light chain levels predict conversion to McDonald 2005 MS within 2 yrs of a first clinical demyelinating event in REFLEX 

S. Roy

  1. P0033 – Baseline serum neurofilament light levels have prognostic value for on-study MRI activity: Results from ASCLEPIOS trials

J. Kuhle

  1. P0037 – Change in serum neurofilament light chain levels: ENSEMBLE 1-year interim results

R. Bermel

  1. P0051 – Comparison of serum and CSF fluid biomarkers for predicting long term disease progression in MS

S. Thebault

  1. P0053 – Correlation Between Spinal Fluid and Blood Levels of Neurofilament Light, GFAP, Tau, and UCHL1: Do We Need a Correction Factor?

E. Alvarez

  1. P0055 – Cross-sectional and longitudinal estimation of radiographic and clinical endpoints to quantify MS disease trajectory with blood serum protein levels.

J. Kuhle

  1. P0057 – Decline in serum neurofilament is associated with decreased clinical and radiological disease activity over two years of dimethyl fumarate treatment 

T. Ziemssen

  1. P0061 – Determining the effect of blood anticoagulants on the detection level of neurobiomarkers in headache and control patients on the SIMOA platform 

A. Ritchie

  1. P0066 – Dimethyl fumarate decreases serum neurofilament light chain in relapsing-remitting multiple sclerosis patients

S. Sainz de la Maza

  1. P0086 – Highly sensitive quantitation of CXCL13 as an intrathecal biomarker in optic neuritis

M. Olesen

  1. P0093 – Increased serum GFAP associates with microstructural white matter damage in multiple sclerosis

M. Saraste

  1. P0097 – Intrathecal immunoglobulin M synthesis is associated with higher serum neurofilament light chain levels and increased MRI disease activity in MS

J. Oechtering

  1. P0098 – Investigation of biomarkers in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders 

B. Arslan

  1. P0111 – Monitoring Multiple Sclerosis Treatment with Plasma Biomarkers: NfL, GFAP, UCH-L1, and Tau

R. Gross

  1. P0118 – Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials

S. Harris

  1. P0119 – Neurofilament light chain levels correlate with lesion activity and axonal damage in MS

A. Van Den Bosch

  1. P0125 – Ocrelizumab treatment induces a sustained blood NfL reduction in patients with PPMS and RMS

A. Bar-Or

  1. P0132 – Prediction of 15-year MS outcomes in BENEFIT trial patients using serum neurofilament light chain concentrations

J. Kuhle

  1. P0137 – Prognostic value of NK/T ratios for disease activity in multiple sclerosis

M. Mimpen

  1. P0152 – Serum Neurofilament levels of multiple sclerosis patients before and after treatment with injectable therapies

A. Huss

  1. P0153 – Serum neurofilament light chain and retinal layer thickness measurements are complementary predictors of disease activity in early multiple sclerosis.

T. Lin

  1. P0154 – Serum Neurofilament light chain captures and predicts disability progression independent of relapses (PIRA) in multiple sclerosis

J. Lorscheider

  1. P0155 – Serum neurofilament light chain levels correlate with attack-related disability in neuromyelitis optica spectum disorder 

O. Aktas

  1. P0156 – Serum neurofilament light levels correlate with reduced grey matter volume in advanced multiple sclerosis

A. Buchmann

  1. P0157 – Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis (RRMS) patients in the CombiRx trial

 G. Cutter

  1. P0158 – Serum neurofilaments in Secondary Progressive Multiple Sclerosis: analysis from the MS-STAT trial 

T. Williams

  1. P0159 – Serum NfL predicts disability progression in MS in a six year longitudinal cohort study

T. Uphaus

  1. P0160 – Serum NfL z-scores derived from a large healthy control group reflect different levels of treatment effect in a real-world setting

P. Benkert

  1. P0164 – Smoking is associated with increased plasma neurofilament light levels in multiple sclerosis

A. Manouchehrinia

  1. P0175 – Towards optimized monitoring of serum neurofilament light chain in MS 

T. Uher

  1. P0180 – Utility of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in tracking treatment response in PPMS patients

J. Giarraputo

  1. P0263 – Serum neurofilament predicts clinical progression and increases diagnostic accuracy in patients with early multiple sclerosis

S. Bittner

  1. PL02.01 – New Insights on Immunopathogenesis

F. Zipp

  1. PS03.05 – Serum glial fibrillary acidic protein, but not S100B or neurofilament light chain predicts future relapses in neuromyelitis optica spectrum disorders

M. Watanabe

  1. PS09.05 – Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice

Ö. Yaldizli

FC=Free Communications   LB=Late Breaking   P=Poster On Demand   PS=Parallel Session  

Link to Late Breaking Posters